Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
In the Literature

ACE inhibition in stable coronary artery disease

Daniel G. Hackam
CMAJ October 28, 2003 169 (9) 939;
Daniel G. Hackam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-88.

Background: Effective secondary prevention strategies for patients with chronic coronary artery disease (CAD) are important for several reasons: (a) the size of this population is enormous and growing every year, particularly owing to continuing increases in life expectancy and decreases in rates of death from acute myocardial infarction; (b) the risk of morbidity and death remains high despite risk-factor modification and treatment with ASA, statins and β blockers; and (c) CAD is the leading cause of death and contributor to health care costs in many regions of the world.1

Question: Does treatment with the angiotensin-converting-enzyme (ACE) inhibitor perindopril reduce cardiovascular risk in a relatively low-risk population with stable CAD and no apparent heart failure?

Design: In this randomized, double-blind, placebo-controlled study, patients with documented evidence of CAD were enrolled if there was no evidence of heart failure, planned revascularization, hypotension, uncontrolled hypertension, renal insufficiency or hyperkalemia. After a 4-week run-in period, during which all patients received perindopril, 12 218 patients were randomly assigned to receive either 8 mg of perindopril once daily or matching placebo for a mean follow-up of 4.2 years. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction and cardiac arrest. Analysis was by intention to treat.

Results: Key baseline characteristics of the patients are shown in Table 1. Loss to follow-up was 0.02%. In all, 10% of the patients given placebo and 8% of those given perindopril experienced the primary end point, for a relative risk reduction [RRR] of 20% (95% confidence interval [CI] 9%–29%; p = 0.0003). The benefit began to appear at 1 year and increased through the course of the trial. The effect of perindopril was consistent across predefined subgroups. Compared with placebo, perindopril was associated with significant reductions in several secondary end points, in particular hospital admission because of heart failure (RRR 39%, 95% CI 17%–56%; p = 0.002) and fatal and nonfatal myocardial infarction (RRR 24%; p < 0.001).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Commentary: The EUROPA study extends previous findings from the landmark Heart Outcomes Prevention Evaluation (HOPE) trial to a substantially lower risk group of patients with stable chronic CAD.2 Key differences between the 2 trials include a much higher incidence of diabetes, peripheral vascular disease and cerebrovascular disease in the HOPE trial and a significantly higher frequency of treatment with antiplatelets, statins and β blockers in the EUROPA trial. Despite these differences, the reductions in major cardiovascular events were largely similar across the 2 trials (e.g., 24% reduction in myocardial infarction in EUROPA v. 20% in HOPE).2 The benefits reported for perindopril in the EUROPA trial appeared to accrue on top of standard preventive therapies (e.g., antiplatelets and β blockers) and were evident regardless of the presence or absence of such risk factors as previous myocardial infarction, hypertension or diabetes.

Practice implications: Seemingly low-risk patients with CAD, such as those with a remote history of myocardial infarction who are otherwise asymptomatic and others with mild stable angina, will benefit from the addition of an ACE inhibitor to an optimal therapeutic regimen consisting of an antiplatelet, β blocker and cholesterol-lowering drug. Selection of a tissue-active ACE inhibitor with a long half-life that has been validated in a large clinical trial (e.g., ramipril or perindopril) is preferable, with every attempt made to match the dose shown to be effective in the trial. After allowing for noncompliance in the EUROPA trial, 1 cardiovascular death or myocardial infarction would be prevented for every 36 patients treated for 4 years with perindopril.3

Daniel G. Hackam Fellow Clinical Pharmacology University of Toronto Toronto, Ont.

References

  1. 1.↵
    Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104(22):2746-53.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53.
    OpenUrlCrossRefPubMed
  3. 3.↵
    White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003;362:755-7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (9)
CMAJ
Vol. 169, Issue 9
28 Oct 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ACE inhibition in stable coronary artery disease
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ACE inhibition in stable coronary artery disease
Daniel G. Hackam
CMAJ Oct 2003, 169 (9) 939;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
ACE inhibition in stable coronary artery disease
Daniel G. Hackam
CMAJ Oct 2003, 169 (9) 939;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Does the choice of β-blocker affect outcome in chronic heart failure?
  • Bisphosphonates and skeletal morbidity in patients with metastatic cancer
Show more In the Literature

Similar Articles

Collections

  • Topics
    • Cardiology: ischemic heart disease
    • Drugs: cardiovascular system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire